ea0035p898 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014
Sala Elisa
, Bellaviti Paola
, Ferrante Emanuele
, Malchiodi Elena
, Verrua Elisa
, Giavoli Claudia
, Profka Eriselda
, Beck-Peccoz Paolo
, Spada Anna
, Mantovani Giovanna
Introduction: The optimal treatment duration for prolactinomas to minimize reccurences is not clear. 2011 Endocrine Society Guidelines suggested that cabergoline withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor volume reduction.Materials and methods: We analyzed 74 patients (mean age=46.9±14.4, M/F=19/56, macro/micro=18/56) bearing a prolactinoma. Patients were divided in 3 groups: Group A (23) tre...